A scoping review of orally available small molecule GLP-1 receptor agonists highlights their potential to replace injectable peptide-based GLP-1 drugs with pills that offer better tissue penetration, longer half-lives, and fixed-dose combination options.
From injection to pillSmall molecule GLP-1 receptor agonists aim to deliver the same benefits as injectable semaglutide and liraglutide in an oral pill format, potentially transforming diabetes and obesity treatment accessibility
What the researchers found
The review identifies several key advantages of small molecule GLP-1 receptor agonists over traditional peptide-based versions:
1. Enhanced oral bioavailability without the absorption enhancers needed by oral semaglutide
2. Better tissue permeability, potentially reaching organs that peptide drugs cannot easily access
3. Extended half-lives enabling convenient once-daily or potentially less frequent oral dosing
4. The ability to create fixed-dose combination pills with other diabetes or cardiovascular drugs
5. Lower manufacturing costs compared to recombinant peptide production
These advantages could address major barriers to GLP-1 therapy adoption, including needle aversion, adherence challenges, and limited combination therapy options with injectable formulations.
Why it matters
The GLP-1 receptor agonist market is one of the fastest-growing in pharmaceutical history, but reliance on injectable peptides limits who can or will use them. Small molecule alternatives could dramatically expand access — no injections, no refrigeration, easy combination with other pills, and potentially lower costs. If these drugs match the efficacy of injectable GLP-1 agonists, they could transform diabetes and obesity treatment from a specialty injection into a simple daily pill.
How the study worked
Scoping review of the preclinical and clinical literature on small molecule (non-peptide) GLP-1 receptor agonists. The review examined the pharmacological profiles, preclinical efficacy data, clinical trial progress, and comparative advantages versus peptide-based GLP-1 receptor agonists for type 2 diabetes management.
What this study cannot tell us
As a scoping review, this paper summarizes existing literature rather than presenting new data. Most small molecule GLP-1 agonists discussed are still in preclinical or early clinical stages, with limited efficacy and safety data compared to the extensive evidence base for injectable peptide GLP-1 drugs. Whether small molecules can match the full therapeutic profile (including cardiovascular and renal benefits) of peptide GLP-1 agonists remains to be demonstrated. Published in a smaller journal, which may limit peer review rigor.
How to read the evidence
This is a scoping review summarizing the field of small molecule GLP-1 receptor agonist development. It synthesizes preclinical and early clinical evidence but does not include novel data or systematic methodology. The evidence for most compounds discussed is still in early stages of development.
When this study was published
Published in 2025, this review captures the current state of a rapidly evolving field. Multiple small molecule GLP-1 agonists are in clinical development, and the landscape could change significantly with upcoming trial results.
The bigger picture
The pharmaceutical industry is intensely focused on oral GLP-1 receptor agonists. While oral semaglutide (Rybelsus) was a first step, it still uses a peptide that requires an absorption enhancer and fasting restrictions. True small molecule GLP-1 agonists would overcome these limitations entirely. Several companies are in advanced clinical development, and the first approvals could fundamentally change how diabetes and obesity are treated — shifting from injectable biologics to conventional oral medications accessible to a much broader patient population.
Questions still open
- Can small molecule GLP-1 agonists achieve the same cardiovascular and renal benefits demonstrated by injectable peptide GLP-1 drugs in major outcome trials?
- Will improved tissue permeability of small molecules produce additional therapeutic effects not seen with peptide GLP-1 drugs?
- How will the cost and accessibility of small molecule GLP-1 pills compare to current injectable options?
Common questions
Why can't current GLP-1 drugs just be made into pills?
When will small molecule GLP-1 pills be available?
Read the original research
Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review.
Journal of Brown hospital medicine, 4(2), 19-32
Citation
Luna Ceron, Eder; Reddy, Sparsha Duvuru; Kattamuri, Lakshmi; Muvva, Durga Mounika; Chozet, Luis; Bright, Tamis. (2025). Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review.. Journal of Brown hospital medicine, 4(2), 19-32. https://doi.org/10.56305/001c.132255